Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3085048 | 0.84 | KMT2A (0.71) | ALDH1A1MAPTKMT2AMEN1MCOLN3 | |
| SCHEMBL3925720 | 0.76 | POLB (0.66) | ALDH1A1KMT2AMEN1POLBHTT | |
| SCHEMBL629436 | 0.72 | ALDH1A1 (0.44) | ALDH1A1MAPTKMT2AMEN1MCOLN3 | |
| SCHEMBL3605815 | 0.69 | L3MBTL1 (0.50) | ALDH1A1MAPTKMT2AMEN1POLB | |
| SCHEMBL3591254 | 0.68 | ALDH1A1 (0.41) | ALDH1A1MAPTKMT2AMEN1MCOLN3 | |
| SCHEMBL28330248 | 0.68 | FAAH (0.43) | MAPTKMT2AMEN1PIK3CAMTOR | |
| SCHEMBL4772848 | 0.67 | PSEN1 (0.63) | ALDH1A1MAPTKMT2AMEN1POLB | |
| SCHEMBL28108051 | 0.67 | MLNR (0.53) | MAPTPOLBPSEN1PSEN2APH1B | |
| SCHEMBL4635552 | 0.67 | KDM4E (0.56) | ALDH1A1MAPTKMT2AMEN1POLB | |
| SCHEMBL1271857 | 0.67 | KMT2A (0.63) | ALDH1A1MAPTKMT2AMEN1MCOLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057140-B1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| EP-2074118-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | AstraZeneca AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| EP-2057140-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-05-13 | — | — | EP | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| WO-2009007748-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008023159-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018134-A1 | Compounds - 945 | MTOR, PIK3CA, PIK3R5 | ALDH1A1 2861/4885MAPT 1124/4885KMT2A 2445/4885 |
| US-20080171743-A1 | Transcutaneous immunostimulation | NFATC1, TLR9, MTOR | ALDH1A1 3243/4885MAPT 2339/4885KMT2A 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.